Identification of Degradant Impurity in Gefitinib by Using Validated RRLC Method


Degradation pathway for gefitinib is established as per ICH recommendations by validated and stability in-dicating reverse phase liquid chromatographic method. Gefitinib is subjected to stress conditions of acid, base, oxidation, thermal and photolysis. Significant degradation is observed in acid and base stress condi-tions. Two impurities are studied among which one impurity is found prominent degradant. The stress sam-ples are assayed against a qualified reference standard and the mass balance is found close to 99.5%. Effi-cient chromatographic separation is achieved on a Agilent make XDB-C18, 50 × 4.6 mm with 1.8 µm parti-cles stationary phase with simple mobile phase combination delivered in gradient mode and quantification is carried at 250 nm at a flow rate of 0.5 mL?min-1. In the developed RPLC method the resolution between ge-fitinib and the potential impurities is found to be greater than 5.0. Regression analysis shows an r value (cor-relation coefficient) of greater than 0.998 for gefitinib and the two potential impurities. This method is capa-ble to detect the impurities of gefitinib at a level of 0.01% with respect to test concentration of 0.5 mg?mL-1 for a 4-µL injection volume. The developed RRLC method is validated with respect to specificity, linearity & range, accuracy, precision and robustness for impurities determination and assay determination.

Share and Cite:

M. Venkataramanna, I. Somaraju and K. Babu, "Identification of Degradant Impurity in Gefitinib by Using Validated RRLC Method," American Journal of Analytical Chemistry, Vol. 2 No. 1, 2011, pp. 75-83. doi: 10.4236/ajac.2011.21008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. H. Lee, J. Y. Han, H. T. Kim and J. S. Lee, “Gefitinib is of More Benefit in Chemotherapy-Naive Patients with Good Performance Status and Adenocarcinoma Histology: Retrospective Analysis of 575 Korean Patients,” Lung Cancer, Vol. 53, No. 3, 2006, pp. 339-345. doi:10.1016/j.lungcan.2006.05.015
[2] K. Kataoka, H. Taniguchi, Y. Hasegawa, Y. Kondoh, T. Kimura, O. Nishiyama, K. Imaizumi, T. Kawabe, H. Kume and K. Shimokata, “Interstitial Lung Disease Associated with Gefitinib,” Respiratory Medicine, Vol. 100, No. 4, 2006, pp. 698-704. doi:10.1016/j.rmed.2005.07.015
[3] Y. M. Yin, Y. T. Geng, X. D. Li, X. L. Hu, X. F. Chen, W. Li and Y. Q. Shu, “Efficacy of Gefitinib as a First-Line Single Agent Treatment in Patients with Advanced Non Small Lung Cancer,” Journal of Nanjing Medical University, Vol. 23, No. 6, 2009, pp. 392-397. doi:10.1016/S1007-4376(09)60088-5
[4] J. Araki, I. Okamoto, R. Suto, Y. Ichikawa and J. Sasaki, “Efficacy of the Tyrosine Kinase Inhibitor Gefitinib in a Patient with Metastatic Small Cell Lung Cancer,” Lung Cancer, Vol. 48, No. 1, 2005, pp. 141-144. doi:10.1016/j.lungcan.2004.10.012
[5] V. K. Kumar, N. A. Raju, S. Begum, J. S. Rao and T. Satyanarayana, “The Estimation of Gefitinib in Tablet Dosage Forms by RP-HPLC,” Research Journal of Pharmacy and Technology, Vol. 2, No. 2, 2009, pp. 341-343.
[6] G. Guetens, H. Prenen, G. De Boeck, W. Van Dongen, E. Esmans, F. Lemiere, A. Van Oosterome, P. Schoffski and E. De Bruijn, “Sensitive and Specific Quantification of the Anticancer Agent ZD1839 (Iressa) in Plasma by On-Column Focusing Capillary Liquid Chromatography-Tandem Mass Spectrometry,” Journal of Chromatography A, Vol. 1 No. 2-5, 2005, p.1082.
[7] “Stability Testing of New Drug Substances and Products,” ICH, Q1A (R2), 2005.
[8] “Photo Stability Testing of New Drug Substances and Products”, ICH, Q1B, 2005.
[9] “Validation of Analytical Procedures: Text and Methodology”, ICH Q2 (R1), 2005
[10] S. W. Baertschi, K. Alsante and R. A. Reed, “Pharmaceutical Stress Testing: Predicting Drug Degradation,” Drugs and the Pharmaceutical Sciences, Informa Healthcare, 2005.
[11] M. Bakshi and S. Singh, “Development of Validated Stability Indicating Assay Methods-Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, 2002, pp. 1011-1040. doi:10.1016/S0731-7085(02)00047-X
[12] “Guidance for Industry: Analytical Procedures and Methods Validation,” US FDA, 2000.
[13] “Validation of Compendial Methods,” The United States Pharmacopeia Convention, 12601 Twinbrook Parkway, Rockville, MD, 20852, ch<1225>, 2009, pp. 2622-2625.
[14] M. E. Swartz and I. S. Krull, “Developing and Validating Stability Indicating Methods,” Pharmaceutical Technology, Vol. 23, No. 6, 2006, p. 46.
[15] J. Ermer and J. H. M. Miller, “Method Validation in Pharmaceutical Analysis: A Guide to Best Practice,” Wiley-VCH, GmbH & Co. KGaA, Weinheim, 2005, pp. 205-208.
[16] D. M. Bliesner, “Validating Chromatographic Methods: A Practical Guide,” Wiley-VCH, GmbH & Co. KGaA, Weinheim, 2006.
[17] J. T. Carstensen and C. T. Rhodes, “Drug Stability Principles and Practices,” 3rd Edition, Marcel Dekker, New York, 2000.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.